This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Whitehead Institute for Biomedical Research. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Michael Torrens-Spence: Innovator in Transgenic Research
Introduction
Michael Torrens-Spence is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of transgenic host cells and their applications in biosynthesis.
Latest Patents
Michael Torrens-Spence holds 2 patents that focus on compositions and methods for the production of salidroside, icariside D2, and their precursors. His latest patents describe transgenic host cells, vectors useful for making these cells, and kits that facilitate their production. The patents also detail transgenic plants that express specific enzymes, such as 4-hydroxyphenylacetaldehyde synthase (4HPAAS) and tyrosol:UDP-glucose 8-O-glucosyltransferase (T8GT). These innovations are crucial for the biosynthesis of salidroside, icariside D2, tyrosol, and 4-hydroxypenylacetaldehyde.
Career Highlights
Michael Torrens-Spence is affiliated with the Whitehead Institute for Biomedical Research, where he conducts his research. His work has been instrumental in advancing the understanding of transgenic technologies and their potential applications in medicine and agriculture.
Collaborations
One of his notable collaborators is Jing-Ke Weng, with whom he has worked on various projects related to transgenic research.
Conclusion
Michael Torrens-Spence is a prominent figure in the field of biotechnology, with a focus on transgenic innovations that have the potential to impact various industries. His contributions continue to shape the future of biosynthesis and genetic engineering.